Equities

ImmuCell Corp

ImmuCell Corp

Actions
  • Price (EUR)3.18
  • Today's Change-0.02 / -0.63%
  • Shares traded400.00
  • 1 Year change-35.10%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 07:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments0.985.7910
Total Receivables, Net2.231.802.72
Total Inventory7.816.043.09
Prepaid expenses0.450.360.27
Other current assets, total----0
Total current assets111416
Property, plant & equipment, net323128
Goodwill, net0.100.100.10
Intangibles, net0.040.060.08
Long term investments------
Note receivable - long term------
Other long term assets0.060.080.03
Total assets444544
LIABILITIES
Accounts payable0.890.790.75
Accrued expenses1.691.090.78
Notes payable/short-term debt000
Current portion long-term debt/capital leases1.431.040.81
Other current liabilities, total0.200.150.20
Total current liabilities4.203.072.53
Total long term debt119.198.33
Total debt12109.14
Deferred income tax------
Minority interest------
Other liabilities, total4.082.221.03
Total liabilities191412
SHAREHOLDERS EQUITY
Common stock0.780.780.78
Additional paid-in capital363636
Retained earnings (accumulated deficit)(12)(6.23)(3.74)
Treasury stock - common(0.14)(0.15)(0.16)
Unrealized gain (loss)------
Other equity, total------
Total equity253033
Total liabilities & shareholders' equity444544
Total common shares outstanding7.757.757.74
Treasury shares - common primary issue0.060.070.07
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.